X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
MT-601 (neldaleucel) is a multi-tumor associated antigen (multiTAA)-specific T cell product candidate which is under phase 1 clinical development for the treatment of relapsed or refractory Non-Hodgkin Lymphoma.
Lead Product(s): Neldaleucel
Therapeutic Area: Oncology Product Name: MT-601
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 22, 2024
Details:
MT-601 utilizes a novel non-genetically modified approach that specifically targets six different tumor antigens upregulated in lymphoma cells. It is currently being investigated for the treatment of lymphoma patients who are relapsed/refractory after or ineligible to anti-CD19 CAR T cell therapies.
Lead Product(s): MT-601
Therapeutic Area: Oncology Product Name: MT-601
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 11, 2023
Details:
MT-601 utilizes a novel non-genetically modified approach that specifically targets six different tumor antigens upregulated in lymphoma cells (Survivin, PRAME, WT-1, NY-ESO-1, SSX-2, MAGEA-4).
Lead Product(s): MT-601
Therapeutic Area: Oncology Product Name: MT-601
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 11, 2023
Details:
MT-401 OTS is a investigational allogeneic MT-401 Off-the-Shelf (OTS) product utilizes a non-genetically modified approach that specifically targets four different antigens upregulated in AML cells (WT-1, Survivin, PRAME, NY-ESO-1).
Lead Product(s): Zedenoleucel
Therapeutic Area: Oncology Product Name: MT-401
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 07, 2023
Details:
MT-401 (zedenoleucel) utilizes a novel non-genetically modified approach that recognizes multiple antigens expressed on tumor cells, thereby designed to minimize tumor escape and is currently being studied in a Phase 2 clinical trial for the treatment of relapsed AML.
Lead Product(s): Zedenoleucel
Therapeutic Area: Oncology Product Name: MT-401
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 10, 2023
Details:
The funding will support the development of company's lead multi-tumor-associated antigen (multiTAA)-specific T cell product candidate, MT-401 (zedenoleucel) for the treatment of patients with AML after hematopoietic stem cell transplant (HSCT).
Lead Product(s): Zedenoleucel
Therapeutic Area: Oncology Product Name: MT-401
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: National Institutes of Health
Deal Size: $2.0 million Upfront Cash: Undisclosed
Deal Type: Funding June 26, 2023
Details:
MT-601, a multiple tumor-associated antigens (multiTAA)-specific T cell product that recognizes six antigens, demonstrated that MT-601 showed anti-tumor activity against lymphoma patients who have relapsed after anti-CD19 CAR T therapy.
Lead Product(s): MT-601
Therapeutic Area: Oncology Product Name: MT-601
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 12, 2023
Details:
MT-601, a multiple tumor-associated antigens (multiTAA)-specific T cell product that recognizes six antigens, demonstrated that MT-601 showed anti-tumor activity against CD19 CAR T refractory lymphoma cells in vitro.
Lead Product(s): MT-601
Therapeutic Area: Oncology Product Name: MT-601
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 31, 2023
Details:
CellReady will perform a variety of services for Marker including R&D, manufacturing, and regulatory activity in support of Marker’s clinical trials, including MT-601, a multi-TAA specific T cell product targeting six cancer antigens, in ongoing non-Hodgkin’s lymphoma trial.
Lead Product(s): MT-601
Therapeutic Area: Oncology Product Name: MT-601
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Recipient: CellReady
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement May 01, 2023
Details:
MT-401 (zedenoleucel) is an allogeneic multi-tumor-associated antigen (MultiTAA)-specific T cell product manufactured under Good Manufacturing Practice (GMP) using donor-derived T cells obtained from apheresis.
Lead Product(s): Zelenoleucel
Therapeutic Area: Oncology Product Name: MT-401
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Lincoln Park Capital
Deal Size: $25.0 million Upfront Cash: Undisclosed
Deal Type: Agreement December 13, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
